Reduced exposure to harmful and potentially harmful smoke constituents with the Tobacco Heating System 2.1

Nicotine and Tobacco Research

Volumn 19, Issue 2, 2017, Pages 168-175

  Lüdicke, Frank ^a   Baker, Gizelle ^a   Magnette, John ^a   Picavet, Patrick ^a   Weitkunat, Rolf ^a  

^a Philip Morris Products SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYPYRENE; 1,3 BUTADIENE; 2 CYANOETHYLMERCAPTURIC ACID; 2 METHYLANILINE; 2 NAPHTHYLAMINE; 3 HYDROXYPROPYLMERCAPTURIC ACID; 3' HYDROXYCOTININE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4 BIPHENYLAMINE; ACETYLCYSTEINE DERIVATIVE; ACROLEIN; ACRYLONITRILE; BENZENE; BIOLOGICAL MARKER; CAFFEINE; CARBON MONOXIDE; COTININE; CREATININE; GLUCURONIDE; MONOHYDROXYBUTENYL MERCAPTURIC ACID; NICOTINE; NITROSONORNICOTINE; PARAXANTHINE; PHENYLMERCAPTURIC ACID; PYRENE; TOBACCO SMOKE; UNCLASSIFIED DRUG; PYRENE DERIVATIVE; SMOKE;

ADULT; AGED; ARTICLE; COMBUSTION; CONTROLLED STUDY; EXPOSURE; FEMALE; HEALTH HAZARD; HEATING; HUMAN; MALE; PLEASURE; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RISK ASSESSMENT; RISK REDUCTION; SATISFACTION; SENSATION; SMOKING; TOBACCO HEATING SYSTEM; ANALYSIS; BLOOD; ELECTRONIC CIGARETTE; EQUIPMENT DESIGN; HARM REDUCTION; HEAT; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SMOKE; SMOKING CESSATION; TIME FACTOR; TOBACCO; TOXICITY; URINE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; ELECTRONIC CIGARETTES; EQUIPMENT DESIGN; HARM REDUCTION; HOT TEMPERATURE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PYRENES; RISK ASSESSMENT; SMOKE; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO; YOUNG ADULT;

EID: 85027520806     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw164     Document Type: Article

References (21)

1. Unverdorben M, Mostert A, Munjal S, et al. Acute effects of cigarette smoking on pulmonary function. Regul Toxicol Pharmacol. 2010;57(2-3):241-246
2. Roethig HJ, Koval T, Muhammad-Kah R, Jin Y, Mendes P, Unverdorben M. Short term effects of reduced exposure to cigarette smoke on white blood cells, platelets and red blood cells in adult cigarette smokers. Regul Toxicol Pharmacol. 2010;57(2-3):333-337. doi:10.1016/j.yrtph.2010.04.005
3. Martin Leroy C, Jarus-Dziedzic K, Ancerewicz J, Lindner D, Kulesza A, Magnette J. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 7: a one-month, randomized, ambulatory, controlled clinical study in Poland. Regul Toxicol Pharmacol. 2012;64(2 suppl):S74-S84. doi:10.1016/j.yrtph.2012.08.006
4. Tricker AR, Kanada S, Takada K, et al. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 6: 6-day randomized clinical trial of a menthol cigarette in Japan. Regul Toxicol Pharmacol. 2012;64(2):S64-S73. doi:10.1016/j.yrtph.2012.08.007
5. Hughes JR, Keely JP. The effect of a novel smoking system-Accord-on ongoing smoking and toxin exposure. Nicotine Tob Res. 2004;6(6):1021-1027
6. Roethig HJ, Feng S, Liang Q, Liu J, Rees WA, Zedler BK. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation Electrically Heated Cigarette Smoking System. J Clin Pharmacol. 2008;48(5):580-591. doi:10.1177/0091270008315316
7. Buchhalter AR, Eissenberg T. Preliminary evaluation of a novel smoking system: effects on subjective and physiological measures and on smoking behavior. Nicotine Tob Res. 2000;2(1):39-43
8. Buchhalter AR, Schrinel L, Eissenberg T. Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes. Nicotine Tob Res. 2001;3(2):111-118. doi:10.1080/14622200110042636
9. Fagerström KO, Hughes JR, Rasmussen T, Callas PW. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control. 2000;9(3):327-333
10. Fagerström KO, Hughes JR, Callas PW. Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine Tob Res. 2002;4(suppl 2):S141-S145. doi:10.1080/146 2220021000032771
11. Lee EM, Malson JL, Moolchan ET, Pickworth WB. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine Tob Res. 2004;6(1):95-102. doi:10.1080/146222 00310001656911
12. Hatsukami DK, Biener L, Leischow SJ, Zeller MR. Tobacco and nicotine product testing. Nicotine Tob Res. 2012;14(1):7-17. doi:10.1093/ntr/ntr027
13. Rees VW, Kreslake JM, O'Connor RJ, et al. Methods used in internal industry clinical trials to assess tobacco risk reduction. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3196-3208. doi:10.1158/1055-9965. EPI-09-0819
14. Kasza KA, Hyland AJ, Bansal-Travers M, et al. Switching between menthol and nonmenthol cigarettes: findings from the U.S. Cohort of the International Tobacco Control Four Country Survey. Nicotine Tob Res. 2014;16(9):1255-1265. doi:10.1093/ntr/ntu098
15. Kavvadias D, Scherer G, Cheung F, Errington G, Shepperd J, McEwan M. Determination of tobacco-specific N-nitrosamines in urine of smokers and non-smokers. Biomarkers. 2009;14(8):547-553. doi:10.3109/13547500903242883
16. Uppsala Monitoring Centre. WHO Drug Dictionary Enhanced (WHO DDE). 2012. www.umc-products.com. Accessed November 3, 2014
17. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127
18. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007;32(5):912-923. doi:10.1016/j.addbeh.2006.06.028
19. Philip Morris Products S.A. A Controlled, Randomised, Open-Label, 3-Arm Parallel Single-Centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days [YVD-CS01-EU]. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2008-2009. http://clinicaltrials.gov/show/NCT00812279 NLM Identifier:NCT00812279. Accessed December 2, 2013
20. FDA (Food and Drug Administration). Guidance for Industry-Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act-Draft Guidance. 2012
21. Forster M, Liu C, Duke MG, McAdam KG, Proctor CJ. An experimental method to study emissions from heated tobacco between 100-200 degrees C. Chem Cent J. 2015;9:20. doi:10.1186/s13065-015-0096-1